Abstract
Oncolytic viruses (OVs) are designed to replicate in, and subsequently lyse cancer cells. Numerous oncolytic virus platforms are currently in development. Here we review preclinical and clinical experience with JX-594, the lead candidate from the targeted and armed oncolytic poxvirus class. JX-594 is derived from a vaccinia vaccine strain that has been engineered for 1) enhanced cancer targeting and 2) has been “armed” with the therapeutic transgene granulocytemacrophage colony stimulating factor (GM-CSF) to stimulate anti-tumoral immunity. Poxviruses have many ideal features for use as oncolytic agents. The development of oncolytic vaccinia viruses is supported by a large safety database accumulated in the smallpox eradication program. In addition, poxviruses have evolved unique capabilities for systemic spread through the blood that can be harnessed for the treatment of metastatic disease. JX-594 demonstrates a high degree of cancer selectivity and systemic efficacy by multiple mechanisms-of-action (MOAs) in preclinical testing. Data from Phase 1 and 2 clinical trials has confirmed that these features result in potent and systemic efficacy in patients with treatment refractory metastatic cancers.
Keywords: Oncolytic poxvirus, JX-594, Cancer, Oncolytic viruses, vaccinia vaccine strain, granulocytemacrophage colony stimulating factor (GM-CSF), metastatic disease, multiple mechanisms-of-action (MOAs)
Current Pharmaceutical Biotechnology
Title:Targeted and Armed Oncolytic Poxviruses for Cancer: the Lead Example of JX-594
Volume: 13 Issue: 9
Author(s): Caroline J. Breitbach, Steve H. Thorne, John C. Bell and David H. Kirn
Affiliation:
Keywords: Oncolytic poxvirus, JX-594, Cancer, Oncolytic viruses, vaccinia vaccine strain, granulocytemacrophage colony stimulating factor (GM-CSF), metastatic disease, multiple mechanisms-of-action (MOAs)
Abstract: Oncolytic viruses (OVs) are designed to replicate in, and subsequently lyse cancer cells. Numerous oncolytic virus platforms are currently in development. Here we review preclinical and clinical experience with JX-594, the lead candidate from the targeted and armed oncolytic poxvirus class. JX-594 is derived from a vaccinia vaccine strain that has been engineered for 1) enhanced cancer targeting and 2) has been “armed” with the therapeutic transgene granulocytemacrophage colony stimulating factor (GM-CSF) to stimulate anti-tumoral immunity. Poxviruses have many ideal features for use as oncolytic agents. The development of oncolytic vaccinia viruses is supported by a large safety database accumulated in the smallpox eradication program. In addition, poxviruses have evolved unique capabilities for systemic spread through the blood that can be harnessed for the treatment of metastatic disease. JX-594 demonstrates a high degree of cancer selectivity and systemic efficacy by multiple mechanisms-of-action (MOAs) in preclinical testing. Data from Phase 1 and 2 clinical trials has confirmed that these features result in potent and systemic efficacy in patients with treatment refractory metastatic cancers.
Export Options
About this article
Cite this article as:
J. Breitbach Caroline, H. Thorne Steve, C. Bell John and H. Kirn David, Targeted and Armed Oncolytic Poxviruses for Cancer: the Lead Example of JX-594, Current Pharmaceutical Biotechnology 2012; 13 (9) . https://dx.doi.org/10.2174/138920112800958922
DOI https://dx.doi.org/10.2174/138920112800958922 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hybrid Compounds & Oxidative Stress Induced Apoptosis in Cancer Therapy
Current Medicinal Chemistry Gene Therapy for Lysosomal Storage Diseases: Progress, Challenges and Future Prospects
Current Pharmaceutical Design Mycotoxins Levels in Human Milk: A Menace to Infants and Children Health
Current Nutrition & Food Science Molecular Imaging Kits for Hexosamine Biosynthetic Pathway in Oncology
Current Medicinal Chemistry Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling
Current Cancer Drug Targets Synthesis and Antitumor Evaluation of Novel N-substituted Norcantharidin Imidazolium Derivatives
Current Organic Synthesis Further Vitamin D Analogs
Current Vascular Pharmacology From TGF-β to Cancer Therapy
Current Drug Targets Withdrawal Notice: Role, Significance and Association of microRNA-10a/b in Physiology of Cancer
MicroRNA Chemoprevention Gene Therapy (CGT): Novel Combinatorial Approach for Preventing and Treating Pancreatic Cancer
Current Molecular Medicine Saponins: the Potential Chemotherapeutic Agents in Pursuing New Anti-glioblastoma Drugs
Mini-Reviews in Medicinal Chemistry Sunitinib (SUTENT, SU11248) Suppresses Tumor Growth and Induces Apoptosis in Xenograft Models of Human Hepatocellular Carcinoma
Current Cancer Drug Targets Chemotherapy for Laryngeal Cancer - An Apoptotic Approach
Current Drug Targets Strategy of Virtual Screening based Discovery of HSP90 C-terminal Inhibitors and Network Pharmacological Analysis
Current Pharmaceutical Biotechnology Regulatory T Cells in Cancer Biology: A Possible New Target for Biochemical Therapies
Mini-Reviews in Medicinal Chemistry MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Antioxidant Nanoparticles for Control of Infectious Disease
Infectious Disorders - Drug Targets HDL Stimulates apoM Secretion
Protein & Peptide Letters A Link Between Chemical Structure and Biological Activity in Triterpenoids
Recent Patents on Anti-Cancer Drug Discovery Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect
Current Medicinal Chemistry